---
title: "Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291157030.md"
description: "Taysha Gene Therapies presented REVEAL Part A Phase 1/2 trial results for TSHA-102 in Rett syndrome. As of May 2026, 12 patients received the treatment with no serious adverse events. The response rate for developmental milestones reached 83% at 6 months and 100% at 12 months. Management stated these efficacy data exceed FDA-aligned thresholds, supporting a potential Biologics License Application (BLA) filing."
datetime: "2026-06-29T13:56:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291157030.md)
  - [en](https://longbridge.com/en/news/291157030.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291157030.md)
---

# Taysha Gene Therapies posts REVEAL Part A Phase 1/2 TSHA-102 Rett syndrome trial presentation

-   Taysha Gene Therapies published safety and efficacy results from REVEAL Part A Phase 1⁄2 trial of TSHA-102 in Rett syndrome. \* As of a May 2026 data cut, 12 patients aged 6-21 received TSHA-102 across low dose (N=4) and high dose (N=8). \* No treatment-related serious adverse events or dose-limiting toxicities were reported; related events were mild-to-moderate, led by elevated liver enzymes (33%). \* Response rate for gaining or regaining at least one developmental milestone was 83% at 6 months, rising to 100% at 12 months. \* Management highlighted the dataset as exceeding an FDA-aligned efficacy threshold, supporting a potential BLA filing tied to a 6-month pivotal interim analysis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)

## Related News & Research

- [Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome](https://longbridge.com/en/news/293788160.md)
- [TSHA: TSHA-102 showed durable, accumulating functional gains and strong safety in Rett syndrome trials](https://longbridge.com/en/news/290435744.md)
- [Alvotech announces successful closure of FDA inspection of manufacturing facility | ALVO Stock News](https://longbridge.com/en/news/294216022.md)
- [Imunon says Phase 3 OVATION 3 ovarian cancer trial enrollment outpaces plan](https://longbridge.com/en/news/294371031.md)
- [Alvotech says FDA closes Reykjavik plant inspection with VAI classification](https://longbridge.com/en/news/294215716.md)